FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000441292> ?p ?o ?g. }

• W2000441292 abstract "To explore efficacy and safety outcomes of topiramate for episodic migraine prevention in community practice.Open-label, multicenter, flexible-dose clinical trial consisting of a 4-week baseline phase, 24-week core phase and an optional 24-week follow-up phase in patients (18-80 years) with episodic migraine treated in community practices outside tertiary care centers.The primary efficacy endpoint was the change in the number of migraine days/28 days (baseline vs. the last 4 weeks of core treatment) Secondary efficacy parameters included aspects of quality of life (QoL) and subjective patient ratings.A total of 360 patients entered the core phase (ITT population); 37.6% (97 patients) discontinued prematurely, mainly due to adverse events (AEs; 23.6%). Mean topiramate dosage was 90 mg/day. Migraine days decreased from 8.30/28 days to 5.65/28 days and QoL (HIT-6 and MIDAS) was improved. Efficacy, tolerability and satisfaction were rated as 'good' or better by 56, 61 and 63% of patients, respectively. A total of 321 of 364 patients (88.2%) reported at least one treatment emergent AE, and the most common during the core phase were paraesthesia (46.4% of 364 patients), fatigue (17.0%), nausea (15.4%), dizziness (12.9%), viral infection (12.9%), weight decrease (12.6%) and impaired concentration (10.2%). Of 227 patients completing the core phase, 199 (88%) participated in the follow-up phase. A total of 187 patients received topiramate and 38 (20.3%) of these stopped treatment prematurely due to insufficient efficacy (6.4%), AEs (4.8%) or other reasons (10.2%). Reduction in migraine days and improvements in QoL (HIT-6) were maintained or improved (MIDAS) during follow-up, and 84% rated their satisfaction with topiramate therapy as 'good to very good'.This community practice study showed that long-term treatment with topiramate in the prevention of episodic migraine was effective and well-tolerated, and it was associated with clinically relevant improvements in several aspects of QoL." @default.
• W2000441292 created "2016-06-24" @default.
• W2000441292 creator A5010396869 @default.
• W2000441292 creator A5010652194 @default.
• W2000441292 creator A5023280553 @default.
• W2000441292 creator A5043387946 @default.
• W2000441292 creator A5048653324 @default.
• W2000441292 creator A5060535485 @default.
• W2000441292 creator A5065530929 @default.
• W2000441292 creator A5066867428 @default.
• W2000441292 date "2010-03-15" @default.
• W2000441292 modified "2023-09-26" @default.
• W2000441292 title "Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting" @default.
• W2000441292 cites W1524547191 @default.
• W2000441292 cites W1789282936 @default.
• W2000441292 cites W1964880531 @default.
• W2000441292 cites W1973511428 @default.
• W2000441292 cites W1980882517 @default.
• W2000441292 cites W1981978896 @default.
• W2000441292 cites W1993987435 @default.
• W2000441292 cites W2003606210 @default.
• W2000441292 cites W2014303986 @default.
• W2000441292 cites W2025168050 @default.
• W2000441292 cites W2045567183 @default.
• W2000441292 cites W2062526596 @default.
• W2000441292 cites W2062818994 @default.
• W2000441292 cites W2083152690 @default.
• W2000441292 cites W2087030391 @default.
• W2000441292 cites W2092134261 @default.
• W2000441292 cites W2097528608 @default.
• W2000441292 cites W2109048238 @default.
• W2000441292 cites W2112749639 @default.
• W2000441292 cites W2118912931 @default.
• W2000441292 cites W2123474211 @default.
• W2000441292 cites W2125350651 @default.
• W2000441292 cites W2141410286 @default.
• W2000441292 cites W2151599925 @default.
• W2000441292 cites W2166530830 @default.
• W2000441292 cites W2412212647 @default.
• W2000441292 cites W2741081034 @default.
• W2000441292 cites W3015167373 @default.
• W2000441292 cites W3141305851 @default.
• W2000441292 doi "https://doi.org/10.1185/03007991003676461" @default.
• W2000441292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20225996" @default.
• W2000441292 hasPublicationYear "2010" @default.
• W2000441292 type Work @default.
• W2000441292 sameAs 2000441292 @default.
• W2000441292 citedByCount "8" @default.
• W2000441292 countsByYear W20004412922012 @default.
• W2000441292 countsByYear W20004412922014 @default.
• W2000441292 countsByYear W20004412922018 @default.
• W2000441292 crossrefType "journal-article" @default.
• W2000441292 hasAuthorship W2000441292A5010396869 @default.
• W2000441292 hasAuthorship W2000441292A5010652194 @default.
• W2000441292 hasAuthorship W2000441292A5023280553 @default.
• W2000441292 hasAuthorship W2000441292A5043387946 @default.
• W2000441292 hasAuthorship W2000441292A5048653324 @default.
• W2000441292 hasAuthorship W2000441292A5060535485 @default.
• W2000441292 hasAuthorship W2000441292A5065530929 @default.
• W2000441292 hasAuthorship W2000441292A5066867428 @default.
• W2000441292 hasConcept C118552586 @default.
• W2000441292 hasConcept C126322002 @default.
• W2000441292 hasConcept C141071460 @default.
• W2000441292 hasConcept C159110408 @default.
• W2000441292 hasConcept C187212893 @default.
• W2000441292 hasConcept C197934379 @default.
• W2000441292 hasConcept C203092338 @default.
• W2000441292 hasConcept C2775944032 @default.
• W2000441292 hasConcept C2777683783 @default.
• W2000441292 hasConcept C2778186239 @default.
• W2000441292 hasConcept C2778375690 @default.
• W2000441292 hasConcept C2778541695 @default.
• W2000441292 hasConcept C2779951463 @default.
• W2000441292 hasConcept C2908647359 @default.
• W2000441292 hasConcept C3019800554 @default.
• W2000441292 hasConcept C535046627 @default.
• W2000441292 hasConcept C71924100 @default.
• W2000441292 hasConcept C99454951 @default.
• W2000441292 hasConceptScore W2000441292C118552586 @default.
• W2000441292 hasConceptScore W2000441292C126322002 @default.
• W2000441292 hasConceptScore W2000441292C141071460 @default.
• W2000441292 hasConceptScore W2000441292C159110408 @default.
• W2000441292 hasConceptScore W2000441292C187212893 @default.
• W2000441292 hasConceptScore W2000441292C197934379 @default.
• W2000441292 hasConceptScore W2000441292C203092338 @default.
• W2000441292 hasConceptScore W2000441292C2775944032 @default.
• W2000441292 hasConceptScore W2000441292C2777683783 @default.
• W2000441292 hasConceptScore W2000441292C2778186239 @default.
• W2000441292 hasConceptScore W2000441292C2778375690 @default.
• W2000441292 hasConceptScore W2000441292C2778541695 @default.
• W2000441292 hasConceptScore W2000441292C2779951463 @default.
• W2000441292 hasConceptScore W2000441292C2908647359 @default.
• W2000441292 hasConceptScore W2000441292C3019800554 @default.
• W2000441292 hasConceptScore W2000441292C535046627 @default.
• W2000441292 hasConceptScore W2000441292C71924100 @default.
• W2000441292 hasConceptScore W2000441292C99454951 @default.
• W2000441292 hasLocation W20004412921 @default.
• W2000441292 hasLocation W20004412922 @default.
• W2000441292 hasOpenAccess W2000441292 @default.
• W2000441292 hasPrimaryLocation W20004412921 @default.

• next